VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc)

VEGFR-2 protein is an important tyrosine protein kinase receptor.As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis.It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization.VEGFR-2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.

VEGFR-2, a tyrosine-protein kinase, serves as a crucial cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing a fundamental role in angiogenesis regulation, vascular development, permeability, and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, and differentiation, as well as the reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, like isoform 2, may function as decoy receptors, particularly in negatively regulating VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the availability of free VEGFA and/or VEGFC and preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling through heterodimer formation. The binding of vascular growth factors to isoform 1 initiates various signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Additionally, it mediates the activation of MAPK1/ERK2, MAPK3/ERK1, AKT1, and the phosphorylation of PIK3R1, contributing to phosphatidylinositol 3-kinase regulation and actin cytoskeleton reorganization. VEGFR-2 is indispensable for VEGFA-induced NOS2 and NOS3 expression, leading to nitric oxide production by endothelial cells, and it phosphorylates PLCG1, FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC.

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ this effect is 4.894 ng/mL in the presence of 5 ng/mL recombinant human VEGF165, corresponding to a specific activity is 2.043×10⁵ units/mg.

• 
  Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells.The ED₅₀ for this effect is 4.894 ng/mL in the presence of 5 ng/mL recombinant human VEGF165, corresponding to a specific activity is 2.043×10⁵ units/mg.

Mouse

HEK293

C-hFc

P35918 (A20-E762)

16542  [NCBI]

ASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLE

Approximately 138.21 kDa

• 
  Greater than 90% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.